In this study, eligible subject will be Subjects will have the opportunity to receive the treatment of Camrelizumab in combination with pemetrexed and carboplatin therapy .
A single-arm, prospective, single-center, phase II, exploratory study investigating Camrelizumab combined with pemetrexed and carboplatin in the treatment of advanced non-squamous cell non-small-scale EGFR mutations (EGFR-TKI treatment failure ) Effectiveness of cell lung cancer patients